Latest Regulatory News

Conrad Asia Energy has locked in a transformative farm-in and financing deal for its flagship Mako gas field, setting the stage for first gas in late 2027. The company also resolved historic disputes, strengthening its position in Indonesia’s growing gas market.

Clarity Pharmaceuticals reports robust progress in prostate cancer and neuroendocrine tumour trials alongside a strong cash position of $226.2 million, underpinning its path towards commercialisation.

Southern Palladium has made significant strides in advancing its Bengwenyama platinum group metals project, completing key drilling and regulatory milestones while securing A$20 million in fresh capital to fund the next development phase.

ReNerve Limited reported a robust 80% increase in quarterly sales driven by strong US market adoption and expanded hospital approvals. The company advances its nerve repair product pipeline with key regulatory milestones and a refreshed board.

4DMedical has rapidly commercialised its CT – VQ™ lung imaging technology following FDA clearance, securing major partnerships and regulatory approvals that position it for significant growth in North America.

Bathurst Resources reported a first-half FY26 EBITDA of NZD 16 million, maintaining its full-year guidance despite export challenges and cost pressures. Key development projects in New Zealand and Canada continue to advance steadily.

Cann Group Limited has reported its first-ever free cash flow positive quarter, following a significant debt restructuring and a $9 million capital raise. Despite a softer quarterly revenue, the company is advancing new product launches and export partnerships, positioning itself for growth.

Actinogen Medical has completed enrolment for its pivotal XanaMIA Alzheimer's trial ahead of schedule, with a positive interim analysis supporting continuation. The company is gearing up for an open-label extension and advancing commercial and partnership strategies.

Stavely Minerals is advancing its 2026 Scoping Study for the Stavely Copper-Gold Project, targeting a significant production scale boosted by strong copper, gold, and silver prices. The company aims to outline a pathway to over 10 years of mine life with a mid-year study delivery.

Alterity Therapeutics has bolstered its Phase 2 data for ATH434 in Multiple System Atrophy and is advancing regulatory plans for a pivotal Phase 3 trial, supported by a robust cash position of A$49.2 million.

ACDC Metals has reported encouraging mineralogy results from its Goschen Central Rare Earth Elements project, reinforcing its strategic value amid rising geopolitical interest. The company maintains a solid cash balance to support ongoing development and exploration activities.

Estrella Resources has reported multiple high-grade manganese intersections at its Ira Miri project, including assays up to 58% manganese, and received regulatory approval for a 30,000-tonne bulk sample extraction. Concurrently, drilling at the Werumata limestone project has been completed with assay results pending.